clinical trial · NCT02077192
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Immune Thrombocytopenic PurpuraFostamatinib Disodium
brief summary
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
started
Oct 1, 2014
primary completion
Jun 2, 2020
completion
Jun 2, 2020
last updated
Dec 11, 2023
official title
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol